Publicly-held biotechnology major Biocon Ltd on Friday announced it had entered into an agreement with the US-based $21-billion Bristol-Myers Squibb (BMS) to further develop its IN-105, an oral insulin product candidate.
Biocon will use BMS’ expertise in clinical trials and get help in redesigning Phase-II trials of the blockbuster drug. Biocon has been working on this drug since 2004 and has so far spent close to $20 million. It had started the programme by partnering US-based Nobex, but later taken control as the latter declared bankruptcy in late 2005.
Technology Partners: MimirTech
Links:
[1] http://admin.indiaenvironmentportal.org.in/news/biocon-gets-us-firm-board-trials-oral-insulin
[2] http://admin.indiaenvironmentportal.org.in/category/newspaper/business-standard-new-delhi
[3] http://admin.indiaenvironmentportal.org.in/category/thesaurus/diabetes
[4] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drugs
[5] http://admin.indiaenvironmentportal.org.in/category/thesaurus/biotechnology-industry
[6] http://admin.indiaenvironmentportal.org.in/category/thesaurus/medical-research
[7] http://admin.indiaenvironmentportal.org.in/category/thesaurus/india
[8] http://admin.indiaenvironmentportal.org.in/category/thesaurus/health
